The NRAS Mutation Analysis Assay is a real-time PCR-based assay designed to detect somatic mutations in exons 2, 3 and 4 of the NRAS gene. A 'Detected' result indicates the presence of any one of the following NRAS mutations: G12D/C/S, G13R/V, K117R, Q61H/L/K/R, A146T and A59D/T. Testing is available separately or in combination with BRAF, HRAS and KRAS in the NGS based RAS/RAF Panel.
NRAS mutations are frequently found in many human cancers, particularly melanoma, acute myeloid leukemia, thyroid cancer and colorectal carcinoma (CRC). NRAS mutations occur most commonly at codon 61 of exon 3. Less commonly, mutations occur at codons 12 and 13 of exon 2, codon 59 of exon 3 and codons 117 and 146 of exon 4. CRC patients with any known NRAS mutation (exons 2, 3, and 4) are associated with resistance to anti-EGFR targeted antibody therapies such as cetuximab or panitumumab. NRAS mutations are present in approximately 20% of melanoma and may predict response to MEK inhibitors.
- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen
7 days